- Sarepta Therapeutics (NASDAQ:SRPT -6.5%) Q1 results: Revenues: $0; R&D Expense: $38.8M (-1.0%); SG&A: $20.9M (-7.9%); Operating Loss: ($59.7M) (+3.6%); Net Loss: ($59.8M) (+2.9%); Loss Per Share: ($1.31) (+12.1%); Non-GAAP Loss Per Share: ($1.15) (unch); Quick Assets: $129.2M (-32.9%).
- No guidance given.
Sarepta Therapeutics Q1 net loss improves by 12%
Recommended For You
More Trending News
About SRPT Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SRPT | - | - |
Sarepta Therapeutics, Inc. |